ABBV
Price
$229.13
Change
-$1.17 (-0.51%)
Updated
Oct 14 closing price
Capitalization
404.77B
16 days until earnings call
Intraday Buy/Sell Signals
NVS
Price
$130.26
Change
+$1.14 (+0.88%)
Updated
Oct 14 closing price
Capitalization
251B
13 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ABBV vs NVS

Header iconABBV vs NVS Comparison
Open Charts ABBV vs NVSBanner chart's image
ABBVIE
Price$229.13
Change-$1.17 (-0.51%)
Volume$5.53M
Capitalization404.77B
Novartis AG
Price$130.26
Change+$1.14 (+0.88%)
Volume$1.56M
Capitalization251B
ABBV vs NVS Comparison Chart in %
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. NVS commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and NVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (ABBV: $229.13 vs. NVS: $130.26)
Brand notoriety: ABBV: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 102% vs. NVS: 116%
Market capitalization -- ABBV: $404.77B vs. NVS: $251B
ABBV [@Pharmaceuticals: Major] is valued at $404.77B. NVS’s [@Pharmaceuticals: Major] market capitalization is $251B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $728.24B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $96.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than ABBV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).

  • ABBV’s TA Score: 4 bullish, 4 bearish.
  • NVS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than NVS.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -1.59% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.98% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.70%. For the same industry, the average monthly price growth was +0.81%, and the average quarterly price growth was +19.36%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 31, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.70% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($405B) has a higher market cap than NVS($251B). ABBV has higher P/E ratio than NVS: ABBV (109.11) vs NVS (18.99). NVS YTD gains are higher at: 38.680 vs. ABBV (32.495). NVS has higher annual earnings (EBITDA): 22.7B vs. ABBV (14.2B). NVS has more cash in the bank: 7B vs. ABBV (6.47B). NVS has less debt than ABBV: NVS (32.6B) vs ABBV (70.5B). ABBV has higher revenues than NVS: ABBV (58.3B) vs NVS (55.2B).
ABBVNVSABBV / NVS
Capitalization405B251B161%
EBITDA14.2B22.7B63%
Gain YTD32.49538.68084%
P/E Ratio109.1118.99575%
Revenue58.3B55.2B106%
Total Cash6.47B7B92%
Total Debt70.5B32.6B216%
FUNDAMENTALS RATINGS
ABBV vs NVS: Fundamental Ratings
ABBV
NVS
OUTLOOK RATING
1..100
2112
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
713
SMR RATING
1..100
1329
PRICE GROWTH RATING
1..100
1349
P/E GROWTH RATING
1..100
1347
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (16) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (90). This means that NVS’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is in the same range as NVS (13). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

ABBV's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as NVS (29). This means that ABBV’s stock grew similarly to NVS’s over the last 12 months.

ABBV's Price Growth Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (49). This means that ABBV’s stock grew somewhat faster than NVS’s over the last 12 months.

ABBV's P/E Growth Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (47). This means that ABBV’s stock grew somewhat faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVNVS
RSI
ODDS (%)
Bearish Trend 8 days ago
39%
Bearish Trend 8 days ago
44%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
53%
Bearish Trend 8 days ago
38%
Momentum
ODDS (%)
Bullish Trend 8 days ago
73%
Bullish Trend 8 days ago
45%
MACD
ODDS (%)
Bullish Trend 8 days ago
64%
Bullish Trend 8 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 8 days ago
44%
Bullish Trend 8 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
62%
Bullish Trend 8 days ago
46%
Advances
ODDS (%)
Bullish Trend 15 days ago
58%
Bullish Trend 15 days ago
50%
Declines
ODDS (%)
Bearish Trend 10 days ago
43%
Bearish Trend 9 days ago
44%
BollingerBands
ODDS (%)
Bearish Trend 8 days ago
33%
Bearish Trend 8 days ago
46%
Aroon
ODDS (%)
Bullish Trend 8 days ago
63%
Bullish Trend 8 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RAMP27.470.31
+1.14%
LiveRamp Holdings
JBIO9.150.06
+0.66%
Jade Biosciences Inc
VACHU10.55N/A
N/A
Voyager Acquisition Corp
OTEX39.07-0.23
-0.59%
Open Text Corp
BYFC7.09-0.12
-1.66%
Broadway Financial Corp

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
-0.51%
AMGN - ABBV
57%
Loosely correlated
+0.49%
MRK - ABBV
51%
Loosely correlated
-1.17%
PFE - ABBV
51%
Loosely correlated
-0.85%
BIIB - ABBV
45%
Loosely correlated
+0.43%
NVS - ABBV
42%
Loosely correlated
+0.88%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.88%
GSK - NVS
69%
Closely correlated
+1.05%
AZN - NVS
62%
Loosely correlated
+0.72%
PFE - NVS
60%
Loosely correlated
-0.85%
JNJ - NVS
55%
Loosely correlated
-0.03%
AMGN - NVS
54%
Loosely correlated
+0.49%
More